Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring

Patients undergoing a polygenic risk score (PRS), metabolic risk score (MRS) and coronary calcium score (CCS) will be randomized to receive PRS and CCS information and followed for the reduction of risk over 12 months. This information will provide information about how to motivate people to adhere to therapy, by providing feedback in a meaningful form to both the clinicians and the patients.

Inclusion criteria

• Asymptomatic subjects age 40-70y
• Statin naïve
• TC ≤ 6.5 mmol/L and LDLC <5 mmol/L, and
• 5 year Australian risk ≥2%.

Exclusion criteria

• Symptomatic coronary, cerebrovascular, or peripheral vascular disease
• Intolerance of statins or currently on statins for any length of time
• Pre-existing muscle disease (eg polymyositis, fibromyalgia) - this may be confused with myalgia from statins
• Patients on drugs that increase the risk of myopathy/rhabdomyolysis such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV/hepatitis C protease inhibitors)
• Atrial fibrillation (interferes with CTCA)
• Chronic kidney disease on haemodialysis (because of vascular calcification) or GFR <50ml/min per 1.73m2 using the Modification of Diet in Renal Disease (MDRD) formula
• Inability to provide informed consent
• Major systemic illness eg. malignancy; rheumatoid arthritis
• Women of child bearing potential (due to performance of CT)
• Poorly controlled hypertension: SBP> 200 and or DBP > 100
• Severe psychiatric disorder (eg bipolar depression; psychosis)
• Patients eligible for treatment based on current Australian guidelines (5 year risk >15%)
• Patients eligible for treatment based on current PBS thresholds TC >7.5 mmol/l and other criteria (see below).